Medium-term outcome of liver recipients from COVID-19 donors
Digestive and Liver Disease
; 55:S27-S28, 2023.
Article
in English
| EMBASE | ID: covidwho-2244913
ABSTRACT
Background:
COVID-19 is associated with thrombotic complications and can result in hepatobiliary injury. Excellent early outcomes have been reported in recipients of solid non-lungs organs from SARS-CoV-2-infected donors, however longer follow-up data are lacking. We aimed to describe the medium-term outcome of our liver transplants (LT) from COVID-19 donors.Methods:
From 11/2020 to 03/2022, we consecutively enrolled all patients who received a graft from COVID-19 donor in our Centre. Protocol liver biopsy and magnetic resonance cholangiopancreatography (MRCP) after 1-year from LT were reported.Results:
In the study period 12/213 (5.6%) adult LT patients received a COVID-19 donor (11 active, 1 resolved COVID-19)1. Eleven patients underwent end-to-end biliary anastomosis and 1 biliodigestive anastomosis. Recipients' and donors' characteristics are reported in table 1. Two recipients tested SARS-CoV-2 RNA positive on nasopharyngeal swab at LT and one was treated with sotrovimab on day-1 after LT. None of the patients developed COVID-19 after LT. One patient underwent hepatic artery thrombectomy at day-1 and died after 320 days for HCC recurrence. Until now -10 patients underwent protocol MRCP (median time from LT 562 days, IQR 245-614), which showed 7 no visible abnormalities, 1 donor-recipient's bile duct size discrepancy, 2 caliber changes <50% at the anastomotic level (untreated for the absence of cholestasis);-7 patients underwent protocol liver biopsy (median time from LT 553 days, IQR 311-557) which showed 1 acute cellular rejection (RAI 4/9) successfully treated with steroids;no signs of fibrosis, rejection or biliopathy in the other 6 patients.Conclusions:
11/12 patients who received a LT from COVID-19 donors are alive, without evidence of SARS-CoV-2 transmission. At a median follow-up of 1.5 years, protocol liver biopsy and MRCP did not show biliopathy, supporting the utilization of COVID-19 donors to expand the donor pool and reduce the waiting list mortality.
sotrovimab; steroid; acute graft rejection; adult; anastomosis; bile duct; bile duct bypass; cholestasis; clinical article; conference abstract; controlled study; coronavirus disease 2019; drug therapy; female; fibrosis; follow up; hepatic artery; hospital admission; human; liver biopsy; liver graft; magnetic resonance cholangiopancreatography; male; mortality; nasopharyngeal swab; nonhuman; outcome assessment; Severe acute respiratory syndrome coronavirus 2; surgery; thrombectomy
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Digestive and Liver Disease
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS